Dear Editor:In emergency departments, haloperidol is the antipsychotic most frequently used to manage violent patients (1) . Although psychiatrists use various typical and atypical antipsychotics for this indication (2) , emergency physicians continue to favour haloperidol. It is a safe and reliable medication for acute aggression (1) , but there are additional factors to consider. For example, most patients requiring an antipsychotic for ongoing treatment will be prescribed a novel or atypical antipsychotic such as risperidone, olanzapine, or quetiapine. Using the same medication for both acute and ongoing treatment improves continuity, reduces risk of relapse while switching medications, and reduces the risk of medication interactions. Moreover, alternate strategies are useful if a patient states a strong medication preference or has experienced an allergic or side effect reaction to a particular medication. Further, patients will sometimes require intramuscular (IM) antipsychotics. However, in Canada, only typical antipsychotics are available in IM formulation. In the US, ziprasidone IM has recently been approved for treatment of acute agitation in patients with schizophrenia (3), while olanzapine IM is moving toward approval in Canada and in the US (3) . Many typical antipsychotics are as safe and effective as haloperidol and can be given IM. These include trifluoperazine, fluphenazine, thiothixene, and loxapine (1, 2) . With regard to the latter, loxapine has a 5-HT 2 -dopamine D 2 receptor occupancy ratio more characteristic of atypical than typical antipsychotics and, thus, a lower risk of extrapyramidal symptoms (2) .
Many hospitals have psychiatrists readily available to the emergency department, yet emergency physicians still regularly manage patients showing acute aggression. Emergency physicians are intermittently exposed to continuing medical education, to pharmaceutical company presentations, and to informal discussions with psychiatry staff regarding medication management of aggression. Nevertheless, haloperidol remains the antipsychotic of choice.
At our centre, postgraduate year 1 emergency medicine (EM) residents are required to complete a 1-month psychiatry rotation. During residency year 2002-2003, EM residents for the first time completed an emergency psychiatry rotation. Each resident was specifically educated in the management of agitation and aggression. This included a didactic session, teaching focused on cases, and supervised case management. At the beginning of their rotations, all 4 EM residents were aware of the haloperidol 5 mg plus lorazepam 2 mg approach to managing aggression. By the end of the rotation, residents were comfortable with some other approaches, including use of loxapine, risperidone, and olanzapine. One resident had the opportunity in the emergency department to use loading dosages of olanzapine 20 mg for 3 different patients showing agitation, with excellent benefit (4). Moreover, in ensuing months, EM residents continued to use these strategies and to discuss them with colleagues.
EM residents benefit from a specific rotation in emergency psychiatry because it is so relevant to their future practice. Further, psychiatry patients benefit from a more patient-centred, individualized approach to medication management, even in the acute setting. 
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Hypothalamic-Pituitary-Adrenal Function and Preventing Major Depressive Episodes
Dear Editor: Depression is associated with dysregualtion of the hypothalamicpituitary-adrenal (HPA) axis (1, 2) . HPA axis dysfunction can produce repeated episodes of hypercortisolemia in depression. Prolonged exposure to elevated cortisol levels may be neurotoxic, especially for brain regions rich in corticosteroid receptors, and may mediate neuronal vulnerability to stressors. Recurrent depression is associated with atrophy of the hippocampus and amygdala (3, 4) and the prefrontal cortex (5). Gradual deterioration of hippocampal feedback inhibition of the HPA axis, owing to downregulation of glucocorticoid receptors from repeated stress, has been demonstrated (6). A recent study has found that an increase in the number of major depressive episodes (MDEs) increases cortisol responses to fenfluramine administration (7). A study of first-episode patients identified memory impairment on neuropsychological testing but no hippocampal volume loss, whereas multiple-episode patients in the same study had both memory impairment and volume loss (8). The results of these and other studies underline the importance of preventing recurrent MDEs.
Antidepressants prevent recurrent MDEs and have a neuroprotecive effect (3, 4, 9) . However, the prevention of MDEs should not be exclusively focused on antidepressive medications. Different types of psychological therapy, social help, vocational rehabilitation, light therapy, exercise, and complementary and alternative treatments may help to prevent recurrent MDEs. For example, mindfulness-based cognitive therapy (MBCT), a group intervention designed to train patients who have recovered from recurrent depression to disengage from dysphoria-activated depressogenic thinking, may prevent relapse or recurrence of depression in patients with a history of 3 or more MDEs (10).
Relapse and recurrence rates for patients with major depression and comorbid psychiatric and medical disorders are greater than rates among patients with depression alone (9). For example, personality disorders may substantially contribute to relapse and recurrence of depression. Therefore, it is important to treat comorbid conditions such as alcohol and substance abuse, personality disorders, and physical illnesses.
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